Intra-Cellular optimistic on lumateperone's future in bipolar despite mixed Phase III results

While one of its trials missed the primary endpoint, Intra-Cellular is hopeful that the robust treatment response seen in the other Phase III lumateperone trial along with a lack of tolerable treatment options for bipolar depression could be sufficient to file for approval.

On Monday, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) fell $1.76 (13%) to $11.70 for a loss of about $97 million in market cap after lumateperone met the primary endpoint in one Phase III trial to

Read the full 750 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE